428 related articles for article (PubMed ID: 26324293)
1. [Statin intolerance].
Graversen CB; Larsen ML; Schmidt EB
Ugeskr Laeger; 2015 Aug; 177(36):. PubMed ID: 26324293
[TBL] [Abstract][Full Text] [Related]
2. Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study.
Cho L; Rocco M; Colquhoun D; Sullivan D; Rosenson RS; Dent R; Xue A; Scott R; Wasserman SM; Stroes E
Cardiovasc Drugs Ther; 2016 Jun; 30(3):297-304. PubMed ID: 26936841
[TBL] [Abstract][Full Text] [Related]
3. Optimizing Cholesterol Treatment in Patients With Muscle Complaints.
Rosenson RS; Baker S; Banach M; Borow KM; Braun LT; Bruckert E; Brunham LR; Catapano AL; Elam MB; Mancini GBJ; Moriarty PM; Morris PB; Muntner P; Ray KK; Stroes ES; Taylor BA; Taylor VH; Watts GF; Thompson PD
J Am Coll Cardiol; 2017 Sep; 70(10):1290-1301. PubMed ID: 28859793
[TBL] [Abstract][Full Text] [Related]
4. Management of the patient with statin intolerance.
Vandenberg BF; Robinson J
Curr Atheroscler Rep; 2010 Jan; 12(1):48-57. PubMed ID: 20425271
[TBL] [Abstract][Full Text] [Related]
5. [Statin intolerance].
Tonstad S
Tidsskr Nor Laegeforen; 2017 Jan; 137(1):36-38. PubMed ID: 28073228
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and Safety of Novel Nutraceutical Formulation Added to Ezetimibe in Statin-Intolerant Hypercholesterolemic Subjects with Moderate-to-High Cardiovascular Risk.
Mazza A; Nicoletti M; Lenti S; Torin G; Rigatelli G; Pellizzato M; Fratter A
J Med Food; 2021 Jan; 24(1):59-66. PubMed ID: 32456525
[TBL] [Abstract][Full Text] [Related]
7. Suggested clinical approach for the diagnosis and management of 'statin intolerance' with an emphasis on muscle-related side-effects.
Sivashanmugarajah A; Fulcher J; Sullivan D; Elam M; Jenkins A; Keech A
Intern Med J; 2019 Sep; 49(9):1081-1091. PubMed ID: 31507054
[TBL] [Abstract][Full Text] [Related]
8. Risk identification and possible countermeasures for muscle adverse effects during statin therapy.
Magni P; Macchi C; Morlotti B; Sirtori CR; Ruscica M
Eur J Intern Med; 2015 Mar; 26(2):82-8. PubMed ID: 25640999
[TBL] [Abstract][Full Text] [Related]
9. Statin-induced myopathy: a review and update.
Abd TT; Jacobson TA
Expert Opin Drug Saf; 2011 May; 10(3):373-87. PubMed ID: 21342078
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and Management of Statin Intolerance.
Alonso R; Cuevas A; Cafferata A
J Atheroscler Thromb; 2019 Mar; 26(3):207-215. PubMed ID: 30662020
[TBL] [Abstract][Full Text] [Related]
11. Expert opinion: the therapeutic challenges faced by statin intolerance.
Patel J; Martin SS; Banach M
Expert Opin Pharmacother; 2016 Aug; 17(11):1497-507. PubMed ID: 27254275
[TBL] [Abstract][Full Text] [Related]
12. Optimizing Statins and Ezetimibe in Guideline-Focused Management.
Bin Abdulhak AA; Robinson JG
Cardiol Clin; 2018 May; 36(2):221-223. PubMed ID: 29609751
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial.
Moriarty PM; Thompson PD; Cannon CP; Guyton JR; Bergeron J; Zieve FJ; Bruckert E; Jacobson TA; Kopecky SL; Baccara-Dinet MT; Du Y; Pordy R; Gipe DA;
J Clin Lipidol; 2015; 9(6):758-769. PubMed ID: 26687696
[TBL] [Abstract][Full Text] [Related]
14. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
[TBL] [Abstract][Full Text] [Related]
15. Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients.
Descamps O; Tomassini JE; Lin J; Polis AB; Shah A; Brudi P; Hanson ME; Tershakovec AM
Atherosclerosis; 2015 Jun; 240(2):482-9. PubMed ID: 25913444
[TBL] [Abstract][Full Text] [Related]
16. [ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
Lancellotti P; Pierard LA; Scheen AJ
Rev Med Liege; 2015 Sep; 70(9):450-5. PubMed ID: 26638446
[TBL] [Abstract][Full Text] [Related]
17. Statin intolerance: now a solved problem.
Sikka P; Kapoor S; Bindra VK; Sharma M; Vishwakarma P; Saxena KK
J Postgrad Med; 2011; 57(4):321-8. PubMed ID: 22120862
[TBL] [Abstract][Full Text] [Related]
18. Current Choice for LDL-C Lowering in High-Risk CVD Patients Intolerant to Statins.
Fras Z
Curr Vasc Pharmacol; 2021; 19(4):398-402. PubMed ID: 33783343
[No Abstract] [Full Text] [Related]
19. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.
Chatzizisis YS; Koskinas KC; Misirli G; Vaklavas C; Hatzitolios A; Giannoglou GD
Drug Saf; 2010 Mar; 33(3):171-87. PubMed ID: 20158283
[TBL] [Abstract][Full Text] [Related]
20. IMPROVE-IT clinical implications. Should the "high-intensity cholesterol-lowering therapy" strategy replace the "high-intensity statin therapy"?
Masana L; Pedro-Botet J; Civeira F
Atherosclerosis; 2015 May; 240(1):161-2. PubMed ID: 25795557
[No Abstract] [Full Text] [Related]
[Next] [New Search]